We have located links that may give you full text access.
Journal Article
Multicenter Study
Hospital incidence, management and direct cost of osteogenesis imperfecta in Spain: a retrospective database analysis.
Journal of Medical Economics 2020 December
OBJECTIVE: The objective of this study was to analyse hospital incidence of osteogenesis imperfecta (OI) in Spanish hospitals and the associated medical costs from a healthcare system perspective.
METHODS: To this aim, a retrospective multicentre study was designed analysing admission records from patients admitted with OI in specialized care settings in Spain between 2000 and 2017. Direct medical costs were calculated based on the diagnosis-related group-based hospital payment systems, determined by the Spanish Ministry of Health.
RESULTS: Overall, 3,747 admissions were reviewed, corresponding to 998 patients, 48.20% of which were males and 51.80% females. Hospital incidence was 5.64 per 100,000 patients (95% CI, 4.80-6.60) over the study period, whereas incidence at birth was 10.14 per 100,000 (95% CI, 8.16-12.05). In-hospital mortality appeared primarily associated to neonatal conditions and acute respiratory failure. Mean length of hospital stay was 2.83 days, decreasing significantly during the study period ( p < 0.0001). Readmission rate was significantly higher in younger patients ( p = 0.0110). In most hospital admissions other disorders of bone and cartilage (osteoporosis and pathologic fractures) were registered, together with delayed growth and hypocalcaemia. The mean annual direct medical cost per hospital admission was €2,571, increasing significantly over the study period ( p < 0.0001).
CONCLUSIONS: Overall, this study provides data that should be taken into account for the development of improved and more efficient treatment protocols, and in reducing the burden of OI at the healthcare system level.
METHODS: To this aim, a retrospective multicentre study was designed analysing admission records from patients admitted with OI in specialized care settings in Spain between 2000 and 2017. Direct medical costs were calculated based on the diagnosis-related group-based hospital payment systems, determined by the Spanish Ministry of Health.
RESULTS: Overall, 3,747 admissions were reviewed, corresponding to 998 patients, 48.20% of which were males and 51.80% females. Hospital incidence was 5.64 per 100,000 patients (95% CI, 4.80-6.60) over the study period, whereas incidence at birth was 10.14 per 100,000 (95% CI, 8.16-12.05). In-hospital mortality appeared primarily associated to neonatal conditions and acute respiratory failure. Mean length of hospital stay was 2.83 days, decreasing significantly during the study period ( p < 0.0001). Readmission rate was significantly higher in younger patients ( p = 0.0110). In most hospital admissions other disorders of bone and cartilage (osteoporosis and pathologic fractures) were registered, together with delayed growth and hypocalcaemia. The mean annual direct medical cost per hospital admission was €2,571, increasing significantly over the study period ( p < 0.0001).
CONCLUSIONS: Overall, this study provides data that should be taken into account for the development of improved and more efficient treatment protocols, and in reducing the burden of OI at the healthcare system level.
Full text links
Related Resources
Trending Papers
Consensus Statement on Vitamin D Status Assessment and Supplementation: Whys, Whens, and Hows.Endocrine Reviews 2024 April 28
The Tricuspid Valve: A Review of Pathology, Imaging, and Current Treatment Options: A Scientific Statement From the American Heart Association.Circulation 2024 April 26
British Society of Gastroenterology guidelines for the management of hepatocellular carcinoma in adults.Gut 2024 April 17
Interstitial Lung Disease: A Review.JAMA 2024 April 23
Ventilator Waveforms May Give Clues to Expiratory Muscle Activity.American Journal of Respiratory and Critical Care Medicine 2024 April 25
Systemic lupus erythematosus.Lancet 2024 April 18
Acute Kidney Injury and Electrolyte Imbalances Caused by Dapagliflozin Short-Term Use.Pharmaceuticals 2024 March 27
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app